Carbon-11-MK 6884

Drug Profile

Carbon-11-MK 6884

Alternative Names: [11C]MK-6884; C-11-MK-6884

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antidementias; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 01 Jan 2016 Phase-I clinical trials in Alzheimer's disease (Diagnosis, In the elderly, In adults) in Belgium (IV) (NCT02621606)
  • 16 Dec 2015 Preclinical trials in Alzheimer's disease (Diagnosis) in USA (IV) before December 2015
  • 16 Dec 2015 Merck Sharp & Dohme plans a phase I trial for Alzheimer's disease (Diagnosis) in USA (IV) (NCT02621606)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top